PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
From:
Mol Cancer Ther. Author manuscript; available in PMC 2010 August 11.
Published in final edited form as:
Mol Cancer Ther. 2009 August; 8(8): 2183–2192.
Published online 2009 August 11. doi: 10.1158/1535-7163.MCT-08-1203

Figure 5

An external file that holds a picture, illustration, etc.
Object name is nihms128024f5.jpg

Where inhibition of singular nodes fails, pre-treatment with a combination therapy sensitizes Huh7 cells to 17AAG, and works as well or better than 17AAG in all cell lines tested. A Double positive populations of Huh7 cells (mean of triplicate+/−SEM as gated in 1A) in response to different treatments at 48hours. The IKK inhibitor is BMS-345541 and was used at 15uM, the PI3K inhibitor is PI103 and was used at 5µM, the JAK inhibitor is Calbiochem JAK inhibitor 1: Pyridone 6, and was used at 3µM. The P-values were obtained by a T-test B The double-positive populations for the listed treatments of Hep3B and FOCUS cells (mean of triplicates +/−SEM) at 48 hours. The P-values were obtained by a T-test. The drug combination is the same as in A.

Images in this article

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
Click on the image to see a larger version.